CELL BIOLOGY INTERNATIONAL is the official journal of the International Federation
for Cell Biology. Our objective is to provide easy-to-assimilate reports of experimental findings (primary research articles) to
as wide a readership as possible in the world. Original Papers, Short (rapid) Communications, Comments, Hypotheses, and Scientific Correspondence
are acceptable. Special issues, Mini-reviews, Book Reviews and Reports on cell biology meetings are normally by invitation. It is our
aim to publish Short Communications within 2 months of acceptance. Abstracts from meetings can be published (either before or after the
event), but the Editor and Publisher have first to be consulted since all cases are customized and the publication of collections of
abstracts, whether online, hardcopy or both, are not published free of charge.
SUBMISSION OF MANUSCRIPTS: Electronic submission
is preferred (see below). Receipt of submissions will be acknowledged within 1 week; this and all further correspondence will be by by
e-mail, unless specifically requested otherwise by the corresponding author. It is imperative therefore that corresponding author gives
full e-mail, telephone and fax contact numbers.
a)For enquiries relating to the submission of articles (including electronic submission
where available) please visit this journal's homepage at http://www.elsevier.com/locate/cellbi. You can track accepted articles
at http://www.elsevier.com/trackarticle and set up e-mail alerts to inform you of when an article's status has changed,
as well as copyright information, frequently asked questions and more.
Contact details for questions arising after acceptance of
an article, especially those relating to proofs, are provided after registration of an article for publication.
Submission to this journal
proceeds totally online. Use the following guidelines to prepare your article. Via the homepage of this journal (http://www.elsevier.com/journals)
you will be guided stepwise through the creation and uploading of the various files. The system automatically converts source files to
a single Adobe Acrobat PDF version of the article, which is used in the peer-review process. Please note that even though manuscript
source files are converted to PDF at submission for the review process, these source files are needed for further processing after acceptance.
All correspondence, including notification of the Editor?s decision and requests for revision, takes place by e-mail and via the author's
homepage, removing the need for a hard-copy paper trail.
The above represents a very brief outline of this form of submission. It
can be advantageous to print this "Guide for Authors" section from the site for reference in the subsequent stages of article preparation.
The format, apart from not being in two columns, should conform precisely to the instructions given, and to the general format of previous
papers in recent issues of the journal. Please note that that the different sections of the article are numbered. It cannot be overemphasised
that the onus is on the author to submit an article that is correctly styled and formatted. Figures should be kept to the smallest
file size possible. Compuscripts that do not comply will be returned for reformatting before they can be accepted, following positive
reviews.
Note: compuscripts submitted to CBI are converted into PDF for the review process, but may need to be edited after acceptance
to follow journal standards. For this, an "editable" file format is necessary, preferably Word for PC.
b) E-mail submission. Authors
should send an electronic version of their article by e-mail to the Editor. However (a) is much preferred.
c) Only in the last resort,
and by prior agreement with the Editor should articles be submitted as hardcopies to the editorial office.
d) Draft compuscripts
or proposal of articles (e.g. including reviews, commentaries, etc.) can be submitted to the main Editorial Office when authors genuinely
wish to ask advice about suitability for the journal, level of the English presentation, ethical considerations, and other matters prior
to formal submission.
Compuscripts can be submitted to one of our Regional Editors (see front cover or editorial board listing on
the web site), where preliminary evaluation will be carried out before the MS is forwarded to the main Editorial Office. Otherwise they
should be sent directly to:
Plant cell papers should initially be submitted to the above Editorial Office, but will subsequently be dealt with by the
Prof John Bryant, School of Biosciences, Exeter University, UK. Tel: 44-29-20-874304; Fax: 44-29-20-874305; E-mail: j.a.bryant@exeter.ac.uk
If the paper is largely about work on cancer cells in vitro, authors will be asked whether they would prefer to publish in CBI, or in
the more suitable open access sister journal, Cancer Cell International.
A CBI number will be assigned to
each article, which should be quoted in all correspondence. Once accepted and passed on to Elsevier for publishing, a proof number that
is not the same as the first CBI number will be generated.
COMPOSITION OF PAPERS: Papers should normally follow the sequence: Title, Authors (indicating
who is responsible for correspondence) and their Affiliations, an Abstract of up to about 150 words, Keywords, Abbreviations, and in
sequentially numbered sections and subsections Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References,
Tables, and Figure Legends.
REVIEWING: At submission, authors can provide details of four named individuals (including fax,
telephone and e-mail addresses) who might act as independent referees. The absence of such information can lengthen the time from submission
to decision. Any Conflicts of Interest should be noted. Revisions of provisionally accepted papers should be returned as soon
as possible, and within 6 months as a maximum where extra work is required. Articles coming in after this period of time has
elapsed will be considered as new submissions, and will require peer reviewing by at least one of the previous referees.
REFERENCES:
Citations should be made by name and year of publication, e.g. (Loewi, 1979). For two-author papers, both names are cited, e.g. (Loewi
and Davis, 1980), but where there are three or more, the et al. abbreviation is used (Loewi et al., 1981), noting the exact punctuation.
Unpublished citations (Loewi, personal communication) are only cited in the text, not in the reference list. References are listed alphabetically.
With two or more same author citations within one year, distinction between them is made by the use of an appended lower case letter
after the year, e.g. (Loewi, 1982a; 1982b). Journal titles are abbreviated, and the following style should be adopted:
Alberts B,
Bray D, Lewis L, Ra. M, Roberts K, Watson JD. Molecular biology of the cell. New York (London): Garland Publishing, 1983.
Song H,
Parsons MR, Rowsell S, Leonard G, Phillips SEV. Crystal structure of intact elongation factor EF-Tu from Escherichia coli in GDP conformation
at 2.05? resolution. J Mol Biol 1999; 285:1245-56.
Mayer F. Cytoskeletons in Eukaryotes and Prokaryotes. In: Fahnestock A, Steinbuchel
A, editors. Polyamides and complex proteinaceous materials I. Biopolymers. Weinheim: Wiley-VCH; 2002. p. 339-75.
When citing an
Elsevier journal, include the digital object identifier (DOI), if noted, from the article's title page. Please note the following examples.
Hongpaisan J. Inhibition of proliferation of contaminating fibroblasts by D-valine in cultures of smooth muscle cells from human
myometrium. Cell Biol Int 2000; 24: 1-7, doi:10.1016/cbir.1999.0448
Creutti SM, Chadi G. S100 immunoreactivity is increased in reactive
astrocytes of the visual pathways following a mechanical lesion of the rat occipital cortex. Cell Biol Int, 2000; doi:10.1016/cbir.2000.0451
ABBREVIATIONS: While authors should avoid unfamiliar abbreviations, a limited number of widely-accepted abbreviations may
be included, these being set out below Keywords on the title page. Other less familiar abbreviations should be quoted in full, followed
by the abbreviation or acronym in brackets at their first mention in the paper. Measurements should be expressed in SI units, and a solidus
should be used, as in g/kg.
ILLUSTRATIONS: Black and white photographs and line-drawings are acceptable. Each should be sequentially
numbered and labelled with the first author's name, address, with an arrow indicating the top of the figure, all this being done in light
pencil on the reverse side of the figure. The publisher will not charge authors for colour figures, essential for the full illustrative
effect of the figures involved. Use of previously published illustrations (and substantive tracts of text) require the appropriate
author's and/or copyright holder's permission, which should be presented at the time of submission of the paper, not afterwards, along
with the full acknowledgement and reference to the original source. For electronic submission, figures should be submitted as EPS (encapsulated
postscript), TIFF, JPG or PDF files. The minimum resolution for electronically submitted photographs is 300 dpi. Links to video clips
can be inserted into papers for movies, but in each case the authors are requested to make their requirements known to the editors both
on the journal and publisher.
DIGITAL OBJECT IDENTIFIER: Elsevier assigns a unique digital object identifier (DOI) to every article
it publishes. The DOI appears on the title page of the article. It is assigned after the article has been accepted for publication and
persists throughout the lifetime of the article. Due to its persistence, it can be used to query Elsevier for information on the article
during the production process, to find the article on the Internet through various web sites and to cite the article in academic references.
When using an Elsevier article in a reference section, it is important to include the article's DOI in the reference, since volume and
page information is not always available for articles published online. The References section, above, shows examples of DOIs included
in references.
COPYRIGHT AND OFFPRINTS: Authors submitting a manuscript do so on the understanding that it has not been submitted
elsewhere, and that, if accepted for publication, exclusive copyright to the paper shall normally be assigned to the Publisher under
US law. The copyright form needs to be signed by all authors (or by an author who has obtained written assent of the non-signing authors).
In consideration for the copyright assignment, the Publisher will provide 50 free offprints of each paper. Further offprints can be ordered
at extra cost on order forms supplied with the proofs. The Publisher will not put any limitation on the personal freedom of the author
to use material in the paper from other works, but permission for each use must be sought from both Publisher and author, and appropriate
citation as to the source of the material must be given with each subsequent use.
IMPORTANT NOTES: Authors submitting Short Communications/Comments and requesting early publication should ensure their MSs are suitable by having them pre-reviewed by an
independent expert themselves. This will reduce the time spent on evaluating them for publication by the Editorial Office.
CELL
LINE AUTHENTICITY, CHARACTERISATION AND FREEDOM FROM CONTAMINATION. This is an important issue, to which authors should pay particular
attention. It is the authors' responsibility to ensure that cell lines used in any study (and the majority do involve them) are
certified as being the designated type, that they have been checked to ensure they are free of contamination (e.g. mycoplasma), and that
they have been used from young stock. These are the three criteria upon which good practice is based, as set out in the UKCCC
Guidelines on the use of cell lines (http://ukcccr.icnet.uk). Attention should be paid to this in the Material and Methods
section, and authors omitting to include evidence of good practice will find that their articles may be delayed until such guarantees
are given.
ACKNOWLEDGEMENTS. Authors should ensure that a proper acknowledgement section is included. Information on grant
support, technical assistance and any other help obtained in the presentation of the article should be included not only out of courtesy,
but also because funding authorities request that work records the number and type of grant(s) involved.
PROOFS. Proofs will
be sent to the author (first-named author if no corresponding author is identified on multi-authored papers) by PDF wherever possible
and should be returned within 48 hours of receipt, preferably by e-mail. Corrections should be restricted to typesetting errors; any
other amendments made may be charged to the author. Any queries should be answered in full. Elsevier will do everything possible to get
your article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all of your corrections
are returned to us in one all-inclusive e-mail or fax. Subsequent additional corrections will not be possible, so please ensure that
your first communication is complete. Should you choose to mail your corrections, please return them to: Log-in Department, Elsevier,
Stover Court, Bampfylde Street, Exeter, Devon EX1 2AH, UK.
AUTHOR ENQUIRIES.
For enquiries relating to the submission of
articles (including electronic submission where available) please visit this journal's homepage at http://www.elsevier.com/locate/cellbi.
You can track accepted articles at http://www.elsevier.com/trackarticle and set up e-mail alerts to inform you of when an
article?s status has changed, as well as copyright information, frequently asked questions and more.
Contact details for questions
arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication.
US National Institutes of Health (NIH) voluntary posting ("Public Access") policy.
Elsevier facilitates author response
to the NIH voluntary posting request (referred to as the NIH "Public Access Policy"; see http://publicaccess/nih.gov/
) by posting the author's peer-reviewed manuscript directly to PubMed Central on request from the author, 12 months after formal publication.
Upon notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com
that your work has received NIH funding and that you intend to respond to the NIH policy request, along with your NIH award number to
facilitate processing. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version of your manuscript that
will include peer-review comments, for posting 12 months after formal publication. This will ensure that you will have responded fully
to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed Central, and any such posting is
prohibited.
Authors' rights:
As an author you (or your employer or institution) may do the following: • make copies
(print or electronic) of the article for your own personal use, including for your own classroom teaching use • make copies
and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues
(but not commercially or systematically, e.g., via an e-mail list or list server) • post a pre-print version of the article
on Internet websites including electronic pre-print servers, and to retain indefinitely such version on such servers of sites •
post a revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on
your personal or institutional website or server, with a link to the journal homepage (on Elsevier.com) • present the article
at a meeting or conference and to distribute copies of the article to the delegates attending such a meeting • for your employer,
if the articles is a 'work for hire', made within the scope of your employment, your employer may use all or part of the information
in the article for other intra-company use (e.g., training) • retain patent and trademark rights and rights to any processes
or procedure described in the article • include the article in full or in part in a thesis or dissertation (provided that this
is not to be published commercially) • use the article or any part thereof in a printed compilation of your works, such as collected
writings or lecture notes (subsequent to publication of your article in the journal) • prepare other derivative works, to extend
the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original
publication in the journal.
